Background
Lung cancer is one of the most common malignant tumors with the highest mortality in the world [
1]. Histopathologically, approximately 50% of lung cancers are lung adenocarcinoma (LUAD) [
2]. In clinical practice, most patients were already at advantage stages when they were first diagnosed with LUAD [
3]. Nowadays, the clinical application of immunotherapy has greatly improved the treatment outcome of patients. However, in advanced LUAD, the response rate of programmed death-1/programmed death-ligand 1 inhibitor monotherapy is only 17–21% [
4]. The optimal treatment strategy for advanced LUAD is still controversial. It is of great importance to seek combined strategies and improve tumor immune microenvironment.
Radiotherapy enhances the immunogenicity of tumor cells [
5], and has a synergistic effect with immunotherapy [
6]. Radioimmunotherapy generates more effective anti-tumor immune responses, but its regulatory mechanism is still being studied. Radiotherapy can active cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway and promote the release of pro-immune cytokines [
5,
7]. Radiation directly induces DNA damage and the formation of micronuclei in cancer cells, and cause DNA single- and double-stranded breaks [
8]. The accumulation of micronuclei and double-stranded DNA in the cytoplasm result in the activation of the cytoplasmic DNA sensor cGAS, which activates the STING/type I interferon (IFN) signaling pathway, promoting the infiltration of CD8
+ T cells in tumors [
9]. DNA damage repair deficiency alone or in combination with radiotherapy enhances the immunostimulatory function through IFN-I signaling pathway [
7].
Sterile alpha motif domain and histidine-aspartate domain-containing protein 1 (SAMHD1) was originally identified in 2000 as an IFN-γ-inducing protein in dendritic cells [
10]. In the past decade, consequent researches revealed that SAMHD1 was a key limiting factor for human immunodeficiency virus infection [
11], and that its mutation caused Aicardi–Goutières syndrome, a hereditary inflammatory encephalopathy caused by excessive interferon (IFN) production [
12]. Recent studies indicated that SAMHD1 formed homo tetramers in the G1 phase, playing a role as deoxy-ribonucleoside triphosphate (dNTP) hydrolase to maintain the balance of dNTP pools [
13]. However, when entering the S phase, SAMHD1 was phosphorylated at T592 to promote degradation of nascent DNA at stalled replication forks and activate the ataxia-telangiectasia-mutated-and-Rad3-related kinase/checkpoint kinase 1 checkpoint. SAMHD1 deletion led to the accumulation of single-stranded DNA (ssDNA) in the cytoplasm and activate the STING signaling pathway [
14]. SAMHD1 also plays important roles in DNA damage repair. It binds to Meiotic Recombination 11 (MRE11) and recruits CtBP interacting protein (CtIP) to the DNA damage sites to promote DNA end resection, activating the DNA damage repair pathway [
15].
Radiotherapy causes DNA damage and activates anti-tumor immunity, and SAMHD1 participates in DNA damage repair and innate immune responses. Therefore, we supposed that the combination of SAMHD1 silencing and radiotherapy might enhance the DNA damage and augment the anti-tumor immunity. Here, we designed experiments in vitro and in vivo to investigate and verify the function of SAMHD1 in anti-tumor immunity and radiotherapy.
Methods
Survival analysis was performed to determine the prognostic value of SAMHD1 with K-M plotter, an online database (
www.kmplot.com). GSEA was performed with the GMT file (c2.KEGG.v6.2 and h.all.v7.1) gene set to download the biological processes from GSEA website (
http://www.broad.nit.edu/gsea). Normalized enrichment score > 1.5 and
P < 0.05 were defined as the significant enrichment pathway. GO and KEGG enrichment analyses were performed using the clusterProfiler package.
P < 0.05 was considered a statistical significance.
Cell lines and cell culture
Human LUAD cell lines, H1299, H1975, A549 and PC9 were cultured in RPMI-1640 Medium (HyClone, USA) containing 10% fetal bovine serum (Gibco, USA) in incubator (37 °C, 5% CO2). The Lewis lung cancer (LLC) cells and RAW264.7 cells were cultured in DMEM medium (HyClone, USA) with 10% fetal bovine serum. All cell lines were obtained from the Type Culture Center of the Chinese Academy of Sciences (Shanghai, China), and authenticated by short tandem repeat analyses.
RNA interference, plasmid and lentiviral transfection
The transfection of small interfering RNAs (siRNAs) targeting SAMHD1, STING and IFI16 synthesized by Genepharma (Suzhou, China) was performed with jetPRIME transfection reagent (Polyplus, France). The transfection of SAMHD1 overexpression plasmid synthesized by Genechem (Shanghai, China) was performed with Lipofectamine 3000 (Thermo Fisher Scientific, USA). LLC cells were infected with short hairpin RNA-Samhd1 lentiviruses synthesized by Genechem and the stably transfected cell lines were obtained by puromycin selection (4 μg/mL). The targeting siRNA sequences were included in the supplementary file (Additional file
1: Table S1).
RNA extraction and quantitative real-time PCR (qPCR)
The total RNA was isolated from cells using TRIzol (Vazyme, Nanjing, China). Total RNA was reversely transcripted into cDNA using hiScript Q RT Supermix with gDNA Eraser (Vazyme). SYBR Green qPCR mix (Vazyme) was used to perform qPCR in the CFX96 RT-PCR System (Bio-Rad, USA). The mRNA relative expression was calculated using 2
−ΔΔCt method. Primer sequences were listed in the supplementary file (Additional file
1: Table S1).
Protein isolation and immunoblotting
The cells were broken by sonication in RIPA lysis buffer (Beyotime Biotechnology, Shanghai, China) containing phosphatase and protease inhibitors (Beyotime) to extract protein. Protein samples were boiled with 5 × loading buffer (Beyotime). SDS-PAGE gels were used to separate samples, which were then transferred to PVDF membranes. After blocking with 5% skimmed milk and incubating with primary antibodies, the bands were detected using an electrochemiluminescence detection kit (Biosharp, Beijing, China) and captured by chemiluminescence imager (Bio-Rad). The primary antibodies were included in the supplementary file (Additional file
1: Table S2).
Immunofluorescence (IF) and immunohistochemistry (IHC)
For IF, adherent cells were fixed with 4% paraformaldehyde fixative (Biosharp) and permeated with 0.5% Triton X-100 (BioFroxx, German). The cells were then blocked with 5% bovine serum albumin (Biosharp) and then incubated with antibodies (Additional file
1: Table S2). Images were captured using a fluorescent microscope (Olympus, Japan) or the Leica STELLARIS 5 confocal microscope (Leica Microsystems, German). For IHC, after antigen retrieval and blocking endogenous peroxidase, the sections were blocked with 3% bovine serum albumin then incubated with antibodies. DAB chromogen was applied and hematoxylin counterstained nuclei. Images were acquired using a light microscope. Hematoxylin and eosin (H&E) staining was conducted to routine protocols.
Enzyme-linked immunosorbent assay (ELISA)
Culture medium was collected from the cells. Using the mouse IFNβ ELISA kits (Bioswamp, Wuhan, China) according to the instructions, the OD values at 450 nm were determined by SpectraMax® Absorbance Reader (Molecular Devices Corporation, USA).
After 48 h of treatments, the cells were seeded into 6-well plates (1000 cells/well) and 96-well plates (1000 cells/well). A CCK8 kit (Meilunbio, Dalian, China) was used to performed CCK8 assays. After 7–10 days of culture, the colonies were fixed with 4% paraformaldehyde, and then stained with 0.5% crystal violet (Beyotime). The numbers of colonies were then counted.
Flow cytometry
For the investigation of ssDNA accumulation, the cells were fixed with 2% paraformaldehyde and then permeated with 0.5% Triton X-100. After that, the cells were blocked with fetal bovine serum and then incubated with the primary antibodies against ssDNA. Then the cells were incubated with secondary antibodies. Cell cycle and apoptosis were performed according instructions. The data were acquired on CytoFLEX system. To analyze CD3
+ and CD8
+ T cell infiltration, as well as macrophage maturation and polarization, the single cell suspensions were prepared from fresh mouse tissues. Fluorescence-labeled antibodies against CD45, CD3, CD4, CD8, CD11b, F4/80, CD86 and MHC-II were then used to stain the cells. The data were acquired on CytoFLEX system and analyzed with FlowJo V10. The antibodies were presented in the supplementary file (Additional file
1: Table S2).
Mice and radiotherapy
To generate a subcutaneous tumor mouse model, wild-type C57BL/6 female mice (WQJX Biotechnology, Wuhan, China) aged 6–7 weeks and housed under SPF conditions were randomly divided into 4 groups using simple randomization. The sample size was decided on previous experience. Mice received injections of negtive control (NC) or shSAMHD1 stable LLC cells (5 × 106 cells in 100 μl PBS) into the right armpits. Tumor volumes were determined using the following formula: (length × width2)/2. Mice were treated with radiotherapy 8 Gy × 3, when tumor volumes reached 500 mm3. Xenografts had ulcerations were excluded from the study. Mice were euthanized once tumor size reached 2000 mm3.The tumor volumes were detected using in vivo imaging system Spectrum 15 days from injection. All animal experiments were approved by Institutional Animal Care and Use Committee at Zhongnan Hospital of Wuhan University.
Statistical analysis
This study used GraphPad Prism to process all the data. Quantitative results were expressed as the mean ± standard deviation. The student’s t-test was used to compare the difference between 2 groups and one-way ANOVA was used to compare 3 or more groups. Survival rates were calculated by the Kaplan–Meier (KM) plots and compared using log-rank tests. P < 0.05 was considered statistically significant.
Discussion
SAMHD1 (72 kDa, 626aa) is located at human chromosome 20q11.23 as a dNTP hydrolase [
26] and a DNA end resection factor [
27], which was involved in DNA damage repair and innate immune responses [
28]. In recent years, SAMHD1 mutations were reported in several cancers, such as colorectal cancer, breast cancer and chronic lymphocytic leukemia [
29]. The functional consequences of SAMHD1 in cancer development and treatment still require further researches. In the colorectal cancer, high expression SAMHD1 correlated with metastasis [
30] and indicated poor prognosis of stage II patients [
31]. Consistent with our results, Eudald Felip et al. found that low expression of SAMHD1 was associated with a positive prognosis in breast, ovarian and non-small cell lung cancer patients [
32].
SAMHD1 was reported to suppress innate immune responses in human monocytic cells and macrophages via inhibiting interferon pathways [
33]. The IFN-I responses in SAMHD1-deficient myeloid cells required the cGAS-STING cytosolic DNA sensing pathway [
25]. Another study showed that SAMHD1 deficiency led to ssDNA accumulate in the cytosol and activated the cGAS-STING pathway to induce IFN-I [
14]. Since cGAS is a DNA sensor which preferentially binds to double-stranded DNA [
34], we wondered how ssDNA activated STING pathway. Ahmed Emam et al. found that the increased cytosolic ssDNA contains ribosomal DNA that can bind to cGAS and activate of the innate immune response [
35]. Kiwon Park et al. found that SAMHD1 prevents R-loop formation to preserve genome integrity [
36]. R-loops, nucleic acid structures containing RNA: DNA hybrids and ssDNAs, could be recognized by cGAS and activate cGAS-STING activity [
37]. Here, we suggested SAMHD1 silencing activated STING pathway through IFI16. IFI16 is a key DNA sensor which could sense ssDNA. The non-canonical IFI16/STING pathway was reported in recent year [
38]. IFI16 could promote production and function of cGAMP [
39] and cooperate with cGAS in the activation of STING [
23]. Our studies suggested that SAMHD1 silencing in LUAD cells caused cytosolic ssDNA accumulation and IFI16 was upregulated and translocated from nucleus to cytosol and then activated STING-IFN-I signaling pathway.
Macrophage constitutes a predominant component of tumor immune microenvironment in lung cancer [
40]. The activation states of macrophages are complex. There are two main macrophage phenotypes, proinflammatory (M1) and anti-inflammatory (M2) macrophages [
41]. M1 macrophages can directly mediate cytotoxicity to kill tumor cells or kill tumor cells by antibody-dependent cell-mediated cytotoxicity [
42]. M1 macrophages can also enhance antigen processing and presentation and T cell responses [
43]. We found that SAMHD1 silencing in lung cancer cells promoted macrophage M1 polarization, which might improve the tumor immune microenvironment.
SAMHD1 promotes DNA end resection which is the initiation of DNA repair by homologous recombination [
15]. SAMHD1 silencing causes homologous recombination deficiency which may sensitize tumor cells to radiotherapy. We verified the combination effects of SAMHD1silencing and radiotherapy on tumor growth inhibition and anti-tumor immunity activation. The combination treatment inhibited cell proliferation, regulated cell cycle and increased apoptosis. In vivo, SAMHD1 deficiency and radiotherapy cooperated to inhibit tumor growth and increased M1 macrophages and CD8
+ T cell infiltration.
There is one therapeutic implication of our findings that SAMHD1 inhibition and radiotherapy may be a rational combination to inhibit tumor growth and enhance anti-tumor immunity. The Vpx protein could induce the degradation of SAMHD1 [
44]. TRIM21 is an E3 ubiqutin ligase, a key regulator of SAMHD1 which specifically degrades SAMHD1 through the proteasomal pathway [
45]. But a protein-based therapy have some limitations and they also have other targets. Selective CDK4/6 inhibitors could control SAMHD1 function by inhibiting its phosphorylation [
46]. CDK4/6 inhibitors might inhibit the DNA end resection ability of SAMHD1 and enhance the dNTP hydrolase function, since SAMHD1 formed homotetramers to Hydrolyze dNTP and was phosphorylated to promote DNA end resection [
28]. We supposed that CDK4/6 inhibitors and radiotherapy might be a promising therapeutic combination for cancer therapy to enhance anti-tumor immune responses. Another potential therapeutic implication is that LUAD with low SAMHD1 expression might receive more benefits and immunostimulatory effects from radiotherapy.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.